V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryContent Uniformity
Lab · The complete guide

Content Uniformity: Uniformity of Dosage Units Explained

In short

Understand how individual-dose testing, appropriate methods and linked manufacturing records support a defensible review of dosage-unit uniformity.

4,057 words · ~19 min read
Content uniformity: a QC analyst in lab coat, glasses and gloves places individual tablets into separate vials for assay beside an HPLC instrument
Content uniformity testing assays individual dosage units to show the active amount is consistent from unit to unit.
On this page
  1. 01What content uniformity measures—and what it does not
  2. 02Content testing, weight variation and neighbouring quality tests
  3. 03Map the product and market before applying guidance
  4. 04Connect blend homogeneity to finished-dose performance
  5. 05Trace non-uniformity to material and process behaviour
  6. 06Sample across the manufacturing sequence, not just convenience
  7. 07Make low-dose preparation part of the analytical review
  8. 08Review acceptance value within the applicable procedure
  9. 09Three worked cases: equal weights, dilution and delivered dose
  10. 10Investigate suspect results without erasing the original evidence
  11. 11Link samples, results, exceptions and accountable batch decisions
  12. 12Implement proportionately and review changes before adoption
On this page · 12 sections
  1. 1What content uniformity measures—and what it does not
  2. 2Content testing, weight variation and neighbouring quality tests
  3. 3Map the product and market before applying guidance
  4. 4Connect blend homogeneity to finished-dose performance
  5. 5Trace non-uniformity to material and process behaviour
  6. 6Sample across the manufacturing sequence, not just convenience
  7. 7Make low-dose preparation part of the analytical review
  8. 8Review acceptance value within the applicable procedure
  9. 9Three worked cases: equal weights, dilution and delivered dose
  10. 10Investigate suspect results without erasing the original evidence
  11. 11Link samples, results, exceptions and accountable batch decisions
  12. 12Implement proportionately and review changes before adoption
AI · Explain it for MY operation

How does Content Uniformity apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01What content uniformity measures—and what it does not

Content Uniformity is a dosage-unit test that measures the amount of active substance in individual units and evaluates the results against specified acceptance criteria. CU test is a common abbreviation. The practical question is whether individual doses contain consistent amounts of active substance—not simply whether the batch average is close to its target.

Uniformity of dosage units is the broader concept, rather than an exact synonym for the content-testing route. For oral liquids, ICH Q6A section 3.3.2.2(a) describes that concept as including both dosage-form mass and active-substance content. This is pharmaceutical guidance, not a universal method-selection rule.

Before interpreting a result, establish four reference points:

  • The dosage unit being evaluated, such as one tablet or capsule.
  • The active substance being measured.
  • The label-claim basis, including the declared amount per unit and reporting units.
  • The applicable test procedure and its specified acceptance criteria.

Formulation evidence explains how the active is distributed; manufacturing evidence describes how units were made; laboratory evidence measures the sampled units. These contribute different information. Use the comparison of neighbouring tests to separate content, mass and batch-average questions, alongside blend uniformity for the mixture-level question. A dosage-unit result should be interpreted within that wider evidence, not treated as a complete description of the process.

02Content testing, weight variation and neighbouring quality tests

Content testing measures active substance in individual dosage units. Weight variation uses a mass-based route; its suitability depends on the applicable procedure and product circumstances. These tests answer different questions from blend sampling or a pooled assay.

Test or conceptWhat is measuredQuestion answeredInterpretation boundary
Content uniformityActive-substance content in individual unitsHow consistently is active substance distributed between doses?Retains unit-level differences rather than pooling them.
Weight variationIndividual-unit mass, interpreted through the applicable procedureCan mass variation support dosage-unit uniformity assessment?Equal weights alone do not establish equal active content.
Uniformity of dosage unitsDosage-form mass or active-substance contentAre dosage units uniform by the selected procedure?An umbrella concept, not a separate assay.
Blend uniformityActive-substance concentration in blend samplesIs the sampled mixture homogeneous?Does not directly measure finished individual doses.
Composite batch assayActive-substance content in a pooled sampleWhat is the pooled sample’s overall potency?Pooling can conceal differences between units.

For pharmaceutical specifications, ICH Q6A section 3.3.2.1(d) includes both dosage-form mass and active-substance content within uniformity of dosage units and generally recommends one route rather than both. This is guidance, not a universal requirement to run two tests.

ICH Q4B Annex 6 section 2.1.1 says weight variation as an alternative to content uniformity is not interchangeable across all ICH regions unless the stated 25 mg/25% threshold is met. That is an interchangeability condition, not a complete method-eligibility rule.

The FDA consideration in Annex 6 section 4.2 rejects the not-more-than-2% RSD exception for regulatory purposes and says content uniformity should be performed for items below that threshold.

Resolve method selection through the product and jurisdiction scope discussed next; keep numerical disposition in the acceptance-value review. Operationally, distinguish routine weight checks from the selected dosage-unit procedure, and use blend uniformity evaluation to address the upstream mixture.

03Map the product and market before applying guidance

Start with the product classification, intended market and dosage form—not a familiar test name. As an operational practice, record these together with the applicable specification and method before deciding which uniformity procedure to use. Keep binding regulatory obligations separate from guidance recommendations and internal manufacturing controls.

Product and jurisdictionAuthority typeRelevant statementOperational scope check
US drug manufacturingRegulation: check applicabilityCheck the current text of 21 CFR 211.110(a)(1) and (a)(3) for scope and applicable in-process requirements.Document the applicable 21 CFR 211 controls separately from the finished-dose acceptance-value procedure.
EU, Japanese and other ICH-region pharmaceuticalsICH guidance; regional implementation checkICH Q4B Annex 6 section 2.1.2 excludes all-region interchangeability for specified dosage forms appearing in local text enclosed by black diamonds.Check regional implementation, dosage-form applicability and the conditions associated with the texts referenced in section 2.1.
Pharmaceutical methods used for FDA purposesICH guidance: FDA considerationICH Q4B Annex 6 section 4.2 describes conditional interchangeability; FDA might request demonstration that the chosen method is acceptable and suitable for the particular material or product.Do not treat the guidance recommendation as a substitute for determining current market and product obligations.
Supplements, food, devices and non-pharmaceutical chemicalsProduct-specific assessment; operational practiceEstablish the applicable classification, market rules and specifications separately.Do not transplant the pharmaceutical framework as a universal requirement. Where relevant, assess the sterile or aseptic supplement boundary.

Dosage form also changes the practical question. For oral liquids, ICH Q6A section 3.3.2.2(a) considers the dosage unit to be the typical dose taken by the patient. The operational assessment should therefore identify the patient-dose quantity rather than defaulting to the whole container; see the measured-dose worked case.

For parenteral powders for reconstitution, ICH Q6A section 3.3.2.3(a) generally considers uniformity-of-mass testing acceptable. Keep that recommendation attached to its dosage-form context rather than extending it to every injectable product.

A useful mapping record names the market, classification, dosage form, applicable procedure and specification, plus the person responsible for resolving scope questions. This is an operational review aid, not an additional legal standard.

04Connect blend homogeneity to finished-dose performance

Blend uniformity evaluation examines material at the blending stage; dosage-unit testing examines individual units after dose formation. Their relationship depends on everything between those sampling points. Neither result substitutes for the other: a homogeneous blend does not establish that subsequent units contain consistent amounts of active substance.

During transfer, particles with different sizes or densities can segregate. Blend hold time, including storage conditions and handling during the hold, can affect distribution or flow. Hopper discharge patterns and feeder behaviour can then change which material reaches the press or filler at a particular production interval.

For oral liquids and powders intended for reconstitution as oral liquids, ICH Q6A section 3.3.2.2(a) recommends verifying adequate product homogeneity during development when new drug products use weight variation above the applicable threshold. This is pharmaceutical guidance, not a universal manufacturing rule.

As operational practice, connect mixing controls to the drug-manufacturing controls mapped above by following the material through discharge, holding and feeding. Link blend identity, transfer sequence, equipment, production interval and finished-unit identity. Comparing two unconnected averages can conceal a local concentration change that affects only part of the run.

Carry that traceability into the sampling design below, using stratified sampling to make manufacturing position part of the evidence rather than treating every sample as interchangeable.

05Trace non-uniformity to material and process behaviour

Use the blend-to-dose relationship to locate the likely point of divergence rather than assuming every variable unit originated in the blender. The following are operational investigation hypotheses and control options, not established batch-specific causes or universal regulatory requirements.

StagePlausible mechanismPractical control or check
FormulationParticle-size or density differences encourage separation; agglomeration creates active-rich clusters.Characterise component size, density and agglomerates.
BlendingIncomplete dispersion, adhesion or electrostatic effects leave active unevenly distributed or retained on surfaces.Check dispersion and residues; assess static-charge mitigation where relevant.
TransferFree fall, vibration or repeated handling promotes segregation.Define transfer height, route and handling conditions; assess discharge segregation risk.
Unit formationUnstable feeding or hopper flow changes the material reaching each unit.Control hopper level and refill conditions; position unit checks around operating events.

Separate changes in delivered powder mass from changes in active concentration: either can change active content per unit, and both can occur together. Compare time-matched unit weights and content results rather than inferring concentration from weight alone.

Long holds, equipment interruptions and restarts deserve targeted checks when settling, adhesion or altered flow is plausible. Test each hypothesis against observations that could support or contradict it: enrichment during hopper drawdown supports a segregation hypothesis; stable concentration across drawdown weakens it. Neither observation alone establishes the batch-specific cause.

06Sample across the manufacturing sequence, not just convenience

As operational practice, distinguish the applicable dosage-unit acceptance-test procedure from supplementary process-characterisation sampling. The latter asks manufacturing questions—such as whether a restart changes unit content—without silently changing the former’s sample selection, test sequence or acceptance rules.

Define five elements before collection:

  • Sampling unit: what constitutes one separately identified dosage unit.
  • Collection point: the equipment outlet, lane, container or other location.
  • Production interval: the time window or unit-count range represented.
  • Collection method: how units are selected and retrieved without preferential picking.
  • Handling conditions: containers, protection, storage and permitted delays before preparation.

Use risk-based stratified sampling to cover early, middle and late production, relevant locations, transfers, stoppages and restarts where these distinctions matter. Explain which process question each interval addresses; an evenly spaced schedule alone may miss a brief disturbance. Scale the coverage to process knowledge and plausible sources of variation rather than treating every event as equally informative.

Retain each unit’s identity and manufacturing position through sample login and handoff. Avoid pooling or relabelling that destroys those relationships. Record convenience sampling, inaccessible locations, damaged units, selection bias and ambiguous collection times as limitations; do not imply that readily collected units represent unobserved production.

Document planned coverage and actual coverage separately, including missed intervals and reasons. A later replacement sample does not recreate the missed manufacturing position. In the article’s lifecycle diagram, connect production position to collection, handling, preparation and individual results. Carry handling conditions and collection limitations into the low-dose analytical review so preparation is assessed against the history of the units actually tested.

From dosage-unit definition to documented disposition
  1. 1
    Define unitIdentify product, market, dose and label-claim basis.
  2. 2
    Select procedureEstablish the applicable method, specification and versions.
  3. 3
    Map risksConnect material behaviour with manufacturing stages.
  4. 4
    Collect unitsPreserve identity, position and collection conditions.
  5. 5
    Test individuallyLink preparations, measurements and calculation records.
  6. 6
    Resolve exceptionsInvestigate discrepancies while preserving original evidence.
  7. 7
    Document dispositionRecord review rationale and the authorised decision.
A practical lifecycle connecting product scope, manufacturing position, individual results and accountable decisions.

07Make low-dose preparation part of the analytical review

As analytical practice, review sample preparation before interpreting low-dose content uniformity results. When little active substance is present, small losses or contamination can materially affect the reported content.

  • Incomplete extraction can leave active substance in the dosage matrix; adsorption onto filters or vessels can reduce recovery.
  • Dilution errors can bias results upward or downward. Carryover from a preceding sample or standard can inflate a subsequent result.
  • Degradation during preparation can reduce measured active substance. Unsuitable working concentrations can place measurements below reliable quantitation or above the usable analytical range.

Review specificity, recovery, precision and usable analytical range for the actual formulation, extraction conditions, filters, holding times and dilution sequence. Set justified, method-specific criteria rather than universal numerical limits; consider how preparation contributes to measurement uncertainty in potency assay.

Repeated injections of one solution assess injection and instrument repeatability, not extraction or dilution variability. Independently prepared dosage units include preparation variability and genuine unit-to-unit differences, so they cannot isolate either contribution alone.

Preserve preparation volumes, dilution factors, unit identity, calculation basis and method version with each result. To test a suspected analytical explanation, plan independent preparation checks alongside instrument checks, such as blanks and standards. Do not automatically attribute low results to manufacturing. Route unresolved preparation or measurement concerns into the failure investigation.

08Review acceptance value within the applicable procedure

For acceptance-value review, start with the current applicable procedure and product specification: use them to establish the definition, calculation and interpretation of acceptance value. As an operational control, keep calculation rules, reference values, limits and any staged decisions together under the correct procedure version. A generic glossary calculation is not a substitute for that controlled set of instructions.

A useful review package links the reported acceptance value to:

  • Individual-unit results and their units.
  • The label-claim basis used to express those results.
  • The analytical method version and calculation version.
  • The applicable decision rule and the documented review outcome.

Separate analytical interpretation from reporting completeness. An interpretable analytical result can still have an incomplete report; an unresolved data-transfer discrepancy leaves uncertainty about which value the reviewer should assess. Resolve missing fields or mismatched values before relying on the reported decision, preserving the original result and documenting any recalculation review.

For the dosage-unit tests discussed in ICH Q6A section 3.3.2.1(d), the guidance contemplates appropriate in-process testing while recommending that acceptance criteria remain in the specification. This is pharmaceutical guidance, not a universal rule for every product sector; see ICH Q6 for context. Use the linked records model to make the reported decision reproducible without substituting a generic acceptance-value formula, sample count or numerical limit.

09Three worked cases: equal weights, dilution and delivered dose

These simplified illustrations show how to reason about individual content, analytical concentration and delivered amount. They are not prescribed sample sizes, acceptance tests or demonstrations of batch disposition. No compendial pass or fail conclusion follows from these calculations.

Case 1: Equal tablet weights, different active contents

Assume five tablets each weigh 100.0 mg and each has a 1.00 mg label claim. Their measured active contents are 0.80, 0.90, 1.00, 1.10 and 1.20 mg.

  • Mean active content = (0.80 + 0.90 + 1.00 + 1.10 + 1.20) mg ÷ 5 = 1.00 mg.
  • Individual content ÷ 1.00 mg × 100 gives 80%, 90%, 100%, 110% and 120% of label claim.

Equal tablet masses and the mean do not describe the individual-content spread. This illustrates why observations of weight uniformity answer a different question. Review question: which observations about material distribution or unit formation would help explain the pattern? Use the process mechanisms discussed above to frame that review; five numbers alone do not identify a cause.

Case 2: Convert concentration back to unit content

Assume a dosage unit with a 1.00 mg label claim is quantitatively extracted to a final volume of 100.0 mL, with no additional dilution.

  • Theoretical concentration = 1.00 mg ÷ 100.0 mL = 0.0100 mg/mL, or 10.0 micrograms/mL.
  • At a measured 0.00940 mg/mL, calculated content = 0.00940 mg/mL × 100.0 mL = 0.940 mg.
  • Percentage of label claim = 0.940 mg ÷ 1.00 mg × 100 = 94.0%.

Review question: do preparation records support the extraction and volume assumptions? Keep those records linked to the unit identified through sample login and handoff. The calculation alone cannot establish whether the lower result originated in the unit or in sample preparation.

Case 3: Concentration versus delivered dose

Assume a homogeneous oral liquid contains 20.0 mg/mL, the intended dose is 5.0 mL, and a hypothetical dosing device delivers 4.5 mL without other losses.

  • Intended amount = 20.0 mg/mL × 5.0 mL = 100.0 mg.
  • Delivered amount = 20.0 mg/mL × 4.5 mL = 90.0 mg, or 90.0% of the intended amount.

Review question: does the sampling approach represent the dose being evaluated? Relate this to the oral-liquid dosage-unit concept above: ICH Q6A section 3.3.2.2(a) describes the typical dose taken by the patient. This example is not a complete test procedure.

10Investigate suspect results without erasing the original evidence

The following is operational investigation practice, not a statement of regulatory requirements. Distinguish an apparent specification failure from an unresolved identity, preparation, calculation or interface problem. Each needs a traceable resolution route; an unexplained discrepancy is not evidence that the batch passes.

  1. Preserve the starting evidence. Retain original results, sample identities, preparation records and relevant production conditions before evaluating alternative explanations. Open a linked investigation through the site's out-of-specification handling process, with an owner and the unresolved question.
  2. Check identity and arithmetic first. Reconcile sample-to-batch assignment, dosage-unit identifiers, units, label-claim basis, transcription and dilution factors. Reconstruct the reported value from its inputs rather than editing the final number until it looks plausible.
  3. Review analytical and manufacturing evidence. Examine preparation execution and analytical performance, then align affected samples with manufacturing chronology, including interruptions and process adjustments. Use observed discrepancies to frame hypotheses; do not assume either laboratory error or manufacturing failure.
  4. Separate follow-up actions. Retesting examines retained sample material; resampling collects additional material; invalidation rejects a result's validity on documented grounds. Define each action's question and rationale before proceeding. Neither favourable-result selection nor repeated testing explains the original observation.
  5. Recover interface exceptions deliberately. In MES-to-LIMS integration, quarantine unmatched records from routine processing, retain the original message, reconcile identifiers and units, and control duplicate processing during replay. Confirm recovery against the intended sample and batch.
  6. Correct additively. Preserve the original entry and link any replacement result to it, recording the reason, author and review. Keep technical correction separate from the accountable human batch decision.

Use the investigation outcome to define a testable corrective action: identify the failure mechanism, expected evidence of improvement and review point in the implementation checklist.

11Link samples, results, exceptions and accountable batch decisions

As a practical record design, connect each batch to its sampled dosage units, each unit to its analytical results, and each result to any investigation and review decision. Disconnected summaries obscure those relationships. Keep dosage-unit identity consistent with the initial definition. This model describes operational relationships, not a specific application database or a universal regulatory record requirement.

  • Identity and context: retain product and batch identifiers, sampled-unit identifiers, dosage-unit definition, label claim and units, and sampling position within the manufacturing sequence.
  • Analytical basis: retain applicable method and specification versions, original results, and calculation records, including inputs and unit conversions as appropriate to the operation.
  • Accountability: link investigations, reviewer identity, decision rationale and disposition to the affected results and batch rather than copying only a conclusion into the batch summary.

For laboratory-to-manufacturing interfaces, agree which system owns each identifier, unit conventions, version handling and acknowledgement status. Specify whether acknowledgement means received, matched or accepted for use; these are different events. For mismatched identifiers or interrupted transfers, use the exception-recovery sequence above. Preserve transfer history and reconcile the receiving record before treating recovery as complete, avoiding duplicate results when a message is resent.

Distinguish missing data, pending review, investigated results and final disposition rather than collapsing them into one pass/fail field. Track these dimensions separately: an investigated result can still await review. Make unresolved items visible during batch release review without overwriting original results.

V5: the batch record brings together lab samples, QC check results, equipment used, checklists, electronic signatures and deviations. Quality review and batch release remain human decisions.

A Linked Dosage-Unit Evidence Model

Batch

Defines product and claim basis.

  • batch_id
  • product_id
  • label_claim
  • label_claim_unit

Unit Sample

Preserves identity and manufacturing position.

  • sample_id
  • batch_id
  • unit_id
  • sampling_position

Analytical Result

Links measurement to its procedure.

  • result_id
  • sample_id
  • method_version
  • content_pct_label_claim

Exception

Connects original evidence and resolution.

  • exception_id
  • result_id
  • original_result_id
  • resolution

Review decision

Records accountable interpretation and disposition.

  • review_id
  • batch_id
  • reviewer_id
  • disposition
Shared identifiers connect original results, exception history and batch decisions.

12Implement proportionately and review changes before adoption

Use this operational-practice checklist to assign ownership before implementation:

  • Regulatory: identify the product and market.
  • Quality and development: define the dosage unit.
  • QC and regulatory: select the applicable procedure.
  • Manufacturing: map process risks.
  • Manufacturing and QC: establish sampling and analytical responsibilities.
  • QC and IT: test record linkage.
  • IT and quality: rehearse exception recovery.
  • Quality: assign review ownership and escalation routes.

Run a limited pilot before expanding the workflow. Test unit identities, calculation reproducibility, version handling, missing records and interrupted imports. Include an audit trail review workflow so reviewers can follow corrections. Evaluate software through concrete record and recovery scenarios, not a feature list presented as proof of regulatory compliance. Keep approval and release decisions with authorised people.

Set change control review triggers for formulation, strength, equipment, transfer, analytical method, dispensing device and specification changes where relevant.

For changes from existing methods to implemented Q4B-evaluated pharmacopoeial texts, ICH Q4B Annex 6 section 4.1 provides guidance to handle change notification, variation and/or prior-approval procedures through established regional regulatory mechanisms for compendial changes.

Questions before expansion

  • Can each result be traced to the collected unit?
  • Can the calculation be reproduced?
  • Are unresolved exceptions visible?
  • Does the selected procedure match the current product and market?

Frequently asked questions

Q.Can a satisfactory [batch assay](/glossary/potency-test-gate) establish uniformity of individual doses?+

No. A pooled assay can conceal differences between units. Assume two tablets each have a label claim of 10 mg, but contain 8 mg and 12 mg respectively. Their combined content is 20 mg, giving an average of 100% of label claim, while the individual contents are 80% and 120%. This illustrates averaging, not a pharmacopoeial acceptance decision. Review individual-dose evidence separately; blend uniformity addresses an upstream question rather than directly measuring every finished-dose population.

Q.When does the 25 mg/25% condition matter to a proposed change from content testing to weight variation?+

It matters when assessing regional interchangeability: ICH Q4B Annex 6, section 2.1.1 says that unless the 25 mg/25% threshold is met, mass/weight variation is not interchangeable with content uniformity in all ICH regions. Separately, ICH Q6A, section 3.3.2.1(d) recommends verifying adequate product homogeneity during development when applying weight variation above the threshold. Route the proposal through change control, documenting dosage form, strength, unit mass, applicable markets and supporting development data.

Q.What should a reviewer check when a laboratory report gives an acceptance value without individual results?+

Treat the acceptance value as a summary requiring traceable support, not as a self-explanatory conclusion. Request individual unit results, sample identities, units, label-claim basis, calculation inputs, rounding rules and the procedure version used. Confirm that the reported calculation can be reproduced and that any omitted or replaced values are identifiable. A LIMS review should connect the summary to underlying measurements and preparation records. Do not infer the applicable acceptance criterion from the reported number alone.

Q.How should [sampling](/glossary/blend-uniformity-stratified-sampling) account for a production stop and restart?+

As a risk-based sampling practice, identify the interruption as a separate production event rather than pooling restart units anonymously with steady-state output. Record stop duration, material remaining in equipment, interventions, restart adjustments and the identities of sampled units. Select sampling positions that can distinguish pre-stop, initial restart and subsequent stable operation, with extent justified by process knowledge. Connect samples to the process event log so reviewers can assess whether any content shift follows the interruption.

Q.What changes when the dosage unit is a measured oral-liquid dose rather than a tablet?+

The focus becomes the dose delivered to the patient, not simply the contents of the bottle. ICH Q6A, section 3.3.2.2(a) describes the dosage unit as the typical dose taken by the patient and states that if dispensing equipment, such as medicine droppers or dropper tips, is an integral part of the packaging, that equipment should be used to measure the dose; otherwise a standard volume measure should be used. Operationally, document the measuring device, dose volume and preparation conditions, including shaking where relevant. For suspensions, keep those conditions consistent when comparing results; gravimetric versus volumetric measurement helps frame the measurement basis.

Q.How can a [low-dose method review](/glossary/ich-q2) distinguish incomplete extraction from genuinely low unit content?+

Investigate recovery before attributing a low result to manufacturing. Compare justified extraction conditions, examine residual solids where feasible, and assess adsorption to filters or containers. Recovery experiments should distinguish extraction from later dilution and measurement steps; adding a standard only after extraction cannot demonstrate recovery from the dosage form. Check sensitivity and preparation precision at the actual test concentration. Satisfactory system suitability alone does not resolve extraction questions, and exploratory results should remain identifiable as investigation work.

Q.How can historical trends inform a review without replacing the current batch evidence?+

Use history to establish context: compare unit-result spread, mean shifts and recurring differences by equipment, production position or material lot. First check comparability of methods, strengths, sampling designs and calculation bases; otherwise an apparent trend may reflect changed measurement conditions. Historical consistency can guide investigation priorities but cannot supply missing observations for the current batch. Link the review to continued process verification, while keeping the current batch’s results and unresolved discrepancies explicit in the disposition assessment.

Q.Which [linked records](/glossary/batch-record) explain why a result was excluded, corrected or replaced after investigation?+

Build a traceable chain from the original sample and preparation records through raw measurements, calculations, investigation findings and the approved conclusion. Distinguish a transcription correction from invalidating an analytical result or testing another unit: each changes the interpretation differently. Preserve the original value alongside the reason, authorisation and replacement relationship. An audit trail review should establish who changed what and when; the investigation should explain the scientific basis. Human reviewers decide whether the resulting evidence supports batch disposition.

Primary sources

  • ICH Q4B Annex 6 Uniformity of Dosage Units
  • ICH Q6A Specifications
Software that covers Content Uniformity
V5 Ultimate (Dietary Supplements)
V5 Ultimate runs Master Manufacturing Records and executed Batch Production Records under 21 CFR Part 111, with mandatory…
Talk to us about Content Uniformity

Want to see how Content Uniformity could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
Dietary SupplementsPharmaceutical
Inside V5
  • → Lab & QC — results against the limit, reviewed by a second person.
  • → QMS — quality records next to the work they concern.
Example reports
V5Ultimate

Sample report

Item QC Specification

Test & release

Item QC SpecificationView on screen or print
V5Ultimate

Sample register

Sampling plans register (CSV)

Test & release

Sampling plans register (CSV)Download CSV
V5Ultimate

Sample register

Test methods register (CSV)

Test & release

Test methods register (CSV)Download CSV
V5Ultimate

Sample report

Sampling Instructions — Product Test Dossier Extract

Test & release

Sampling Instructions — Product Test Dossier ExtractView on screen or print
→ All example reports
Regulatory anchors
  • USP <905>
  • EP 2.9.40
  • 21 CFR 111.75
Related terms
  • → ICH Q1A
  • → Probiotic CFU

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC